Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment
Quantitative measurement of SARS-CoV-2 neutralizing antibodies is highly expected to evaluate immune status, vaccine response, and antiviral therapy. The Elecsys® Anti-SARS-CoV-2 S (Elecsys® anti-S) was developed to measure anti-SARS-CoV-2 S proteins. We sought to investigate whether Elecsys® anti-S...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477342/?tool=EBI |
| _version_ | 1818022449045831680 |
|---|---|
| author | Satomi Takei Tomohiko Ai Takamasa Yamamoto Gene Igawa Takayuki Kanno Minoru Tobiume Makoto Hiki Kaori Saito Abdullah Khasawneh Mitsuru Wakita Shigeki Misawa Takashi Miida Atsushi Okuzawa Tadaki Suzuki Kazuhisa Takahashi Toshio Naito Yoko Tabe |
| author_facet | Satomi Takei Tomohiko Ai Takamasa Yamamoto Gene Igawa Takayuki Kanno Minoru Tobiume Makoto Hiki Kaori Saito Abdullah Khasawneh Mitsuru Wakita Shigeki Misawa Takashi Miida Atsushi Okuzawa Tadaki Suzuki Kazuhisa Takahashi Toshio Naito Yoko Tabe |
| author_sort | Satomi Takei |
| collection | DOAJ |
| description | Quantitative measurement of SARS-CoV-2 neutralizing antibodies is highly expected to evaluate immune status, vaccine response, and antiviral therapy. The Elecsys® Anti-SARS-CoV-2 S (Elecsys® anti-S) was developed to measure anti-SARS-CoV-2 S proteins. We sought to investigate whether Elecsys® anti-S can be used to predict neutralizing activities in patients’ serums using an authentic virus neutralization assay. One hundred forty-six serum samples were obtained from 59 patients with COVID-19 at multiple time points. Of the 59 patients, 44 cases were included in Group M (mild 23, moderate 21) and produced 84 samples (mild 35, moderate 49), while 15 cases were included in Group S (severe 11, critical 4) and produced 62 samples (severe 43, critical 19). The neutralization assay detected 73% positive cases, and Elecsys® anti-S and Elecsys® Anti-SARS-CoV-2 (Elecsys® anti-N) showed 72% and 66% positive cases, respectively. A linear correlation between the Elecsys® anti-S assay and the neutralization assay were highly correlated (r = 0.7253, r2 = 0.5261) than a linear correlation between the Elecsys® anti-N and neutralization assay (r = 0.5824, r2 = 0.3392). The levels of Elecsys® anti-S antibody and neutralizing activities were significantly higher in Group S than in Group M after 6 weeks from onset of symptoms (p < 0.05). Conversely, the levels of Elecsys® anti-N were comparable in both groups. Three immunosuppressed patients, including cancer patients, showed low levels of anti-S and anti-N antibodies and neutralizing activities throughout the measurement period, indicating the need for careful follow-up. Our data indicate that Elecsys® anti-S can predict the neutralization antibodies in COVID-19. |
| first_indexed | 2024-12-10T03:28:36Z |
| format | Article |
| id | doaj.art-0522f3e5687a44da9445b7ef2f11f3bb |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T03:28:36Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-0522f3e5687a44da9445b7ef2f11f3bb2022-12-22T02:03:52ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01179Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessmentSatomi TakeiTomohiko AiTakamasa YamamotoGene IgawaTakayuki KannoMinoru TobiumeMakoto HikiKaori SaitoAbdullah KhasawnehMitsuru WakitaShigeki MisawaTakashi MiidaAtsushi OkuzawaTadaki SuzukiKazuhisa TakahashiToshio NaitoYoko TabeQuantitative measurement of SARS-CoV-2 neutralizing antibodies is highly expected to evaluate immune status, vaccine response, and antiviral therapy. The Elecsys® Anti-SARS-CoV-2 S (Elecsys® anti-S) was developed to measure anti-SARS-CoV-2 S proteins. We sought to investigate whether Elecsys® anti-S can be used to predict neutralizing activities in patients’ serums using an authentic virus neutralization assay. One hundred forty-six serum samples were obtained from 59 patients with COVID-19 at multiple time points. Of the 59 patients, 44 cases were included in Group M (mild 23, moderate 21) and produced 84 samples (mild 35, moderate 49), while 15 cases were included in Group S (severe 11, critical 4) and produced 62 samples (severe 43, critical 19). The neutralization assay detected 73% positive cases, and Elecsys® anti-S and Elecsys® Anti-SARS-CoV-2 (Elecsys® anti-N) showed 72% and 66% positive cases, respectively. A linear correlation between the Elecsys® anti-S assay and the neutralization assay were highly correlated (r = 0.7253, r2 = 0.5261) than a linear correlation between the Elecsys® anti-N and neutralization assay (r = 0.5824, r2 = 0.3392). The levels of Elecsys® anti-S antibody and neutralizing activities were significantly higher in Group S than in Group M after 6 weeks from onset of symptoms (p < 0.05). Conversely, the levels of Elecsys® anti-N were comparable in both groups. Three immunosuppressed patients, including cancer patients, showed low levels of anti-S and anti-N antibodies and neutralizing activities throughout the measurement period, indicating the need for careful follow-up. Our data indicate that Elecsys® anti-S can predict the neutralization antibodies in COVID-19.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477342/?tool=EBI |
| spellingShingle | Satomi Takei Tomohiko Ai Takamasa Yamamoto Gene Igawa Takayuki Kanno Minoru Tobiume Makoto Hiki Kaori Saito Abdullah Khasawneh Mitsuru Wakita Shigeki Misawa Takashi Miida Atsushi Okuzawa Tadaki Suzuki Kazuhisa Takahashi Toshio Naito Yoko Tabe Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment PLoS ONE |
| title | Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment |
| title_full | Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment |
| title_fullStr | Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment |
| title_full_unstemmed | Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment |
| title_short | Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment |
| title_sort | performance evaluation of the roche elecsys r anti sars cov 2 immunoassays by comparison with neutralizing antibodies and clinical assessment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477342/?tool=EBI |
| work_keys_str_mv | AT satomitakei performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT tomohikoai performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT takamasayamamoto performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT geneigawa performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT takayukikanno performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT minorutobiume performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT makotohiki performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT kaorisaito performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT abdullahkhasawneh performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT mitsuruwakita performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT shigekimisawa performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT takashimiida performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT atsushiokuzawa performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT tadakisuzuki performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT kazuhisatakahashi performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT toshionaito performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment AT yokotabe performanceevaluationoftherocheelecsysantisarscov2immunoassaysbycomparisonwithneutralizingantibodiesandclinicalassessment |